MedTrace Logo

PF-04191834 Single Dose Bronchodilatory Study In Asthma.

NCT00723021 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2013-02-01

Study results available
· View outcomes & findings →

Summary

Study to determine the bronchodilatory effects of PF-04191834 compared with zileuton in patients with asthma

Conditions

Interventions

DRUG

PF-04191834

30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.

DRUG

PF-04191834

100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.

DRUG

PF-04191834

2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose

DRUG

zileuton

1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.

DRUG

Placebo

2 x placebo tablets + placebo oral dispersion, single dose.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-12-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00723021 on ClinicalTrials.gov